REZOLUTE, INC. Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price
REZOLUTE, INC. (RZLT) had Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price of $8.64 per share as of 2026-06-30, per its 10-K filed 2026-09-24.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue · last filed 2026-09-24
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price $8.64.
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price $9.16.
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price $9.23.
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price $7.71.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price |
|---|---|
| 2026-06-30 | $8.64 10-K · filed 2026-09-24 |
| 2026-03-31 | $9.16 10-Q · filed 2026-05-12 |
| 2025-12-31 | $9.23 10-Q · filed 2026-02-12 |
| 2025-09-30 | $7.71 10-Q · filed 2025-11-06 |
| 2025-06-30 | $4.57 10-K · filed 2026-09-24 |
| 2024-06-30 | $1.31 10-K · filed 2025-09-17 |
| 2023-06-30 | $3.73 10-K · filed 2024-09-19 |
| 2022-06-30 | $3.51 10-K · filed 2023-09-14 |
| 2021-06-30 | $12.41 10-K · filed 2022-09-15 |
| 2020-03-31 | $0.21 10-Q · filed 2020-05-14 |
| 2019-12-31 | $0.21 10-Q · filed 2020-02-12 |
| 2019-09-30 | $0.21 10-Q · filed 2019-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |